Mesenchymal Stem Cell Therapy Development
Mesenchymal stem cell (MSC) have the ability to self-renew, meaning that they can divide and generate more MSCs, as well as differentiate into different types of cells, depending on the needs of the body. They also have immunomodulatory properties, which means that they can help regulate the immune system and reduce inflammation. CD BioSciences has launched a development service for rheumatoid arthritis stem cell therapies, dedicated to advancing the treatment of this disease.
Overview of Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be found in various tissues throughout the body, chiefly found in bone marrow (BM), as well as adipose tissue, Wharton's gliadin, peripheral blood, umbilical cord, placenta, amniotic fluid and dental pulp. MSCs have the ability to differentiate into various cell types, such as bone cells, cartilage cells, and fat cells. MSCs are able to migrate to areas of tissue damage to promote immune regulation, secrete anti-inflammatory cytokines and evade the immune system. And MSCs are of great potential in anti-inflammatory, anti-aging, reconstruction and wound healing.
Effect of MSC-based regenerative medicine (Margiana, R., et al., 2022)
Applications of MSCs in Regenerative Medicine
MSCs transplantation (MSCT) has shown promising therapeutic results in the treatment of neurological diseases. For instance, in amyotrophic lateral sclerosis (ALS), spinal cord injury (SCI), Parkinson's disease (PD), MSCT has great potential of providing safe and effective treatment of neurological diseases, inhibiting disease progression and significantly improving the quality of life and clinical performance of patients.
The potential of MSCs to differentiate into endodermal lineages makes them an attractive alternative for the treatment of liver disease, in which MSCT can meaningfully improve the clinical performance of these patients, reduce liver fibrosis and inhibit disease progression.
Inflammation plays an important role in renal cell injury and subsequent cell regeneration, and it has been proven that MSCs support for acute and chronic kidney injury. With MSCT treatment, increased renal blood flow, decreased hypoxia, renal vein inflammatory cytokines and angiogenic factors are observed in patients with autosomal dominant polycystic kidney disease (ADPKD).
When cardiomyocytes are damaged by ischemia and other factors, the remaining surviving cardiomyocytes are limited in their ability to proliferate and the dead cardiomyocytes are altered by non-contractile fibrous tissue, leading to dysfunction and triggering the progression of heart failure (HF). The MSCT treatment is an effective, achievable and safe procedure that can significantly improve cardiac function and enhance the quality of life of patients.
Bone regeneration is a critical issue, including fractures, defects, osteoarthritis and osteoporosis. Intra-articular infusion of MSCs together with hyaluronic acid has been proven to be a safe and viable process that leads to a clinical and functional improvement in knee osteoarthritis.
Treating the wound skin with MSCs promotes skin regeneration and reduces scar formation. MSCs perform their functions by migrating to the site of skin injury, suppressing inflammation, and increasing the growth and differentiation of fibroblasts, epidermal cells and endothelial cells.
Our Services
CD BioSciences offers mesenchymal stem cell therapy development services. Our stem cell therapy development services are provided in diseases included but not limited as follows:
As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.
Reference
- Margiana, R., Markov, A., Zekiy, A.O. et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther 13, 366 (2022).
For research use only, not for clinical use.
